SRRK Scholar Rock Holding Corp
FY2025 10-K
Scholar Rock Holding Corp (SRRK) filed its fiscal year 2025 10-K annual report with the SEC on Mar 3, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
- • New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
Management Discussion & Analysis
- • Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
- • R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
Risk Factors
- • FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
- • Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
Financial SummaryXBRL
Revenue
$0
Net Income
-$378M
ROE
-154.0%
Total Assets
$404M
EPS (Diluted)
$-3.29
Operating Cash Flow
-$300M
Source: XBRL data from Scholar Rock Holding Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Scholar Rock Holding Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.